To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time

The aim of the study is:
To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the pharmacodynamics of lanthanum polystyrene sulfonate powder in hyperphosphatemia patients with end-stage renal disease on hemodialysis (ESRD-HD); To evaluate the pharmacokinetics of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia after multi-dose and multiple administration.

Start Date21 Oct 2020

Sponsor / Collaborator

Liaoning Nuokang Bio-Pharmaceutical Co. Ltd.

[+1]

NCT03451019

/ CompletedPhase 4IIT

Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease

Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormones regulating mineral-bone metabolism.

Start Date01 Mar 2018

Sponsor / Collaborator

Medical University of Lodz

[+1]

JPRN-UMIN000030503

/ SuspendedNot ApplicableIIT

The study about the effect of combination therapy of active form of vitamin D and lanthanum carbonate for serum concentration of FGF23 - CVD-LAF study

Start Date20 Jan 2018

Sponsor / Collaborator

Fujita Health University

100 Clinical Results associated with Lanthanum carbonate

100 Translational Medicine associated with Lanthanum carbonate

100 Patents (Medical) associated with Lanthanum carbonate

1,283

Literatures (Medical) associated with Lanthanum carbonate

01 Jul 2025·ENVIRONMENTAL POLLUTION

Lanthanum supplementation at the heading stage efficiently reduces cadmium content in rice by regulating key genes involved in cadmium uptake, translocation, and redistribution pathways

Article

Author: Xiong, Zhiting ; Zhang, Shuai ; Yang, Hua ; Long, Jian ; Xiao, Caixia ; Li, Sen ; Li, Jie

Lanthanum (La) can enhance crop growth while mitigating cadmium (Cd) accumulation in the edible parts of plants. This study determined the optimal timing of La application‒specifically at the rice heading stage‒to maximize yield and suppress Cd accumulation in grains. In pot experiments, La application at the heading stage increased the grain weight by 24.6 % and reduced Cd content in grains by 60.5 %. La treatment at this stage enhanced the transfer index (TF_IN2-N1) of Cd by 29.95 % and reduced TF_N1-IN1 by 29.86 %. Low-dose La in hydroponics further inhibited Cd accumulation while supporting growth. Additionally, La treatment significantly reduced Cd levels in root cell sap and xylem sap and downregulated the expression of critical Cd transporter genes, including OsNramp5, OsNramp1, OsIRT1, and OsHMA2 in the roots and OsZIP7 in the nodes. These results reveal that La application at the heading stage minimizes Cd accumulation in rice grains by limiting Cd uptake, translocation, and redistribution through targeted gene downregulation, establishing this stage as key for maximizing yield and ensuring safer rice production.

01 May 2025·Clinical Journal of the American Society of Nephrology

Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis

Article

Author: Noma, Hisashi ; Hamano, Takayuki ; Mizukami, Aya ; Kimura, Hiroshi ; Yamada, Shunsuke ; Hasegawa, Takeshi ; Nishimoto, Masatoshi ; Fukagawa, Masafumi ; Nishiwaki, Hiroki ; Taniguchi, Masatomo ; Murashima, Miho ; Saito, Hirotaka

Key Points:

Sevelamer was associated with lower all-cause mortality compared with calcium-based agents.Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents.Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents.

Background:

It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients.

Methods:

From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve.

Results:

A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo.

Conclusions:

Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).

01 Mar 2025·BIOLOGICAL TRACE ELEMENT RESEARCH

State-of-the-art Investigation on the Role of Indium, Terbium, Yttrium, and Lanthanum in Recurrent Pregnancy Loss

Article

Author: AlSheikh, Yazeed A ; Abudawood, Manal ; Tabassum, Hajera ; Alrashed, May ; Binhassan, Sarah ; Alrashoudi, Reem Hamoud ; Fatima, Yaqoot ; Fatima, Sabiha ; Ali, Mir Naiman

We aimed to explore the role of Indium (In), Terbium (Tb), Yttrium (Y), and Lanthanum (La) in the serum of women with recurrent pregnancy loss (RPL) and compare them to controls. Additionally, the study aimed to examine the relationship between REE levels and oxidative DNA damage, to identify potential risk factors contributing to RPL. This case-control study included 30 RPL cases and 30 controls with uncomplicated pregnancy. Inductively Coupled Plasma Mass Spectrometer was used to evaluate levels of In, Tb, Y, and La in the serum samples in both groups. The relationship between REE levels, Total Antioxidant Capacity (TAC), and DNA damage was studied by correlation analysis. There was a significant increase in levels of In, Tb, Y, and La in the serum of the RPL group in contrast to the control group (P < 0.001). Furthermore, a negative correlation was observed between increased Y, Tb, La, and TAC in RPL cases (significant at P < 0.05), indicative of weakened antioxidant defenses. Moreover, increased levels of Y, Tb, and La exhibited a positive correlation with the DNA damage marker, statistically significant at P < 0.05. These findings highlight the potential role of oxidative stress-induced DNA damage and metal intoxication in the development of RPL, underscoring the importance of further research to clarify underlying mechanisms and develop preventive strategies.

News (Medical) associated with Lanthanum carbonate

20 Dec 2024

·www.prnewswire.com

Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection

DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes, such as bacteria, becoming resistant to antibiotics. A leading factor in this rise is the improper use and disposal of antibiotics in the environment. Effluents from wastewater treatment plants often contain various antibiotics including trimethoprim (TMP), which can harm ecosystems by disrupting microbial communities essential for nutrient cycling. In addition to contributing to AMR, TMP poses various health risks to humans through indirect exposure. Continue Reading Scientists developed a simple TMP detection device for on-site monitoring of contaminated wastewater using selenite-enriched lanthanum hydroxide electrode and polyimide-filter microfluidic channel. Traditional methods for TMP detection such as capillary electrophoresis and liquid chromatography with mass spectrometry, are often labor-intensive and time-consuming. Electrochemical (EC) methods can provide respite from these issues by offering exceptional sensitivity, real-time analytical capabilities and the potential for miniaturization. Professor Tae Yoon Lee and Dr. Natarajan Karikalan of Chungnam National University, Korea, have made a pioneering advancement in EC detection methods, that shows promise to revolutionize on-site testing for TMP in contaminated wastewater. They developed a disposable microfluidic lab-on-a-chip (LOC) EC sensor, μTMP-chip, designed for real-time TMP detection. "Efficient TMP monitoring in effluents is critical for effective control protocols. Hence, we aimed to enable in situ testing of water samples," explains Prof. Lee. Their paper was made available online on September 21, 2024 and was published in Volume 499 of Chemical Engineering Journal on November 1, 2024. The researchers designed the disposable chip by combining a special electrode made with lanthanum hydroxide and selenite, with a polyimide (PI) filter in a microfluidic channel. The analyses showed that the addition of selenite improved the electrode's ability to detect chemicals by allowing better charge flow. Additionally, the PI filter improved the μTMP-chip's real-time performance, while the efficiency dropped by 15 to 45% when the filter was removed. Additionally, the filter helped trap and isolate unwanted materials and prevented the risk of microbial growth, which could interfere with the sensor's function. The μTMP-chip sensor demonstrated impressive results in real-world testing, showing recovery rates of 94.3 % to 97.6 % in soil and water samples. These results, obtained through wireless testing, highlight the chip's potential for practical use in monitoring environmental samples. "Our current design may face challenges in detecting TMP in highly polluted environments with significant matrix interferences. However, we hope our research will inspire further exploration into developing affordable and efficient TMP detection chips," said Prof. Lee. The researchers believe that their innovative lab-on-a-chip design has the potential to improve the feasibility of on-site, real-time tracking of environmental contaminants leading to improved conservation of ecosystems and human health. Reference Title of original paper: Microfluidic sensor integrated with selenite-enriched lanthanum hydroxide and in situ filtration for the on-site detection of the antibiotic trimethoprim in environmental samples Journal: Chemical Engineering Journal DOI: 10.1016/j.cej.2024.155982 About the institute Website: Media Contact: Gaeun Kim +82 42-821-6239 [email protected] SOURCE Chungnam National University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

01 Jun 2024

·www.globenewswire.com

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. The published abstract titled “Preclinical characterization of pretargeted radioimmunotherapy with GD2-SADA, a self-assembling and disassembling bispecific fusion protein” characterizes the binding properties of GD2-SADA across several GD2-expressing cell lines and lanthanide metal-DOTA complexes, while also demonstrating its anti-tumor efficacy when used with Lutetium 177 (Lu177)-DOTA in a two-step approach to pretargeted radioimmunotherapy (“PRIT”). In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors. GD2-SADA binding was significantly improved by a p53-derived domain that drives the self-assembly and disassembly (“SADA”) of GD2-SADA tetramers, which possess four distinct GD2-binding domains that cumulatively enhance binding. Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys. “We believe that these data further validate GD2-SADA's promise as a novel targeted radioimmunotherapy and support the continued advancement of our SADA PRIT technology platform and clinical programs,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals. By contrast, GD2-SADA showed negligible binding to trace metal-DOTA complexes or empty DOTA, an important consideration for the targeted delivery of the radioactive payload in patients. “We are especially encouraged by the selective binding of GD2-SADA to lanthanide metal-DOTA complexes with current and emerging applications in the diagnosis and targeted treatment of solid tumors,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. Taken together, the binding properties of the GD2-SADA protein provide a pharmacological basis for the robust and dose-responsive anti-tumor effects of GD2-SADA Lu177 PRIT in vivo, also presented in this seminal research. These findings have paved the way for the clinical development of GD2-SADA PRIT in adults and adolescents with GD2-positive tumors (NCT05130255). Y-mAbs will be available for comment at booth #35151 on the Exhibition Floor of McCormick Place. Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2023 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans, including potential partnerships; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product and SADA as a differentiated radioimmunotherapy platform positioning the Company on a path to potentially transform the treatment paradigm for a variety of cancers and improve patients’ lives; expectations relating to key anticipated development milestones, including potential expansion of international commercialization efforts with respect to DANYELZA development efforts and the SADA Technology, including potential indications and applications, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. Investor Contact:Courtney DuganVP, Head of Investor Relationscdu@ymabs.com

ImmunotherapyLicense out/inASCODrug ApprovalClinical Study

02 Jan 2024

·www.businesswire.com

Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States

PARSIPPANY, N.J.--( BUSINESS WIRE )--Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma. As of January 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC Numbers. Natco Pharma USA is led by Subba Rao Mente, Chief Executive Officer. Julie Trendowicz and Nick DiMaio, the former Executive Vice President and President of DASH, respectively, will assume the same roles under Natco Pharma USA. “ By acquiring DASH, Natco Pharma has gained a strategic presence in the United States, connecting us directly with our valued customers in this crucial market,” said Subba Rao Mente, Chief Executive Officer of Natco Pharma USA. “ This strategic move isn't just about growth; it's about bolstering our commitment to the U.S. pharmaceutical landscape.” Since 2007, Natco Pharma has been active in the US market, forging co-development and licensing partnerships with leading U.S. generic pharmaceutical companies. The company’s collaborative efforts have culminated in the successful development and launch of a range of first-to-market generics and complex formulations, including Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets, and Lapatinib Tablets. These launches have firmly established Natco Pharma as a formidable and trustworthy entity in the U.S. generic pharmaceutical industry, laying the groundwork for a large-scale expansion into the U.S. With the establishment of Natco Pharma USA, the company hopes to continue to increase accessibility and affordability of its generic products. About Natco Pharma Limited Natco Pharma Limited (Natco Pharma) is an R&D-focused pharmaceutical company based in Hyderabad, India, with subsidiaries in North America, Latin America, Australia, and Southeast Asia. With nearly 4,500 employees worldwide, the company develops, manufactures, and markets Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) with a focus on niche therapeutic areas and complex products. The company's products reach more than 40 countries globally through its own subsidiaries and partnerships, where Natco products are out-licensed to multinational companies and companies with strong local and regional presence in their respective geographies. About Natco Pharma USA Based in New Jersey, Natco Pharma USA is the U.S. Sales and Marketing company for all DASH products, as well as current, future and non-committed products developed and manufactured by Natco Pharma. The company's growing product catalog includes products across multiple therapeutic areas. Natco Pharma USA has various opportunities for collaborating, including a variety of profit-share and supply-chain initiatives such as Co-Development/Co-Ownership of ANDAs, Licensing of ANDAs, Acquisition of NDAs/ANDAs, and Authorized Generics. For more information, please visit www.natcopharmausa.com .

AcquisitionLicense out/in

100 Deals associated with Lanthanum carbonate

External Link

KEGG	Wiki	ATC	Drug Bank
D04667	Lanthanum carbonate	V03AE03	DB06792

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperphosphatemia	Austria	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Belgium	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Bulgaria	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Denmark	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Estonia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Finland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	France	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Hungary	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Iceland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Ireland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Italy	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Latvia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Lithuania	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Luxembourg	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Malta	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Netherlands	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Norway	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Slovakia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Slovenia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Spain	Takeda Pharmaceuticals International AG	01 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	Japan	Bayer AG	01 Jun 2010
Chronic Kidney Diseases	Phase 3	Japan	Shire Plc	01 Jun 2010
Chronic kidney disease, Stage V	Phase 3	United States	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	Germany	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	Puerto Rico	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	United Kingdom	Shire Plc	05 Jan 2007
Calciphylaxis	Phase 1	United States	Shire Plc	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02209636 (Pubmed \| Kidney360)	Phase 4	Chronic Kidney Diseases serum phosphorus \| oxidative stress \| vascular dysfunction	54	Lanthanum carbonate	mjxjrbiktx(vcqkpittjw) = lauptogxha keuoxnchwx (sirouvrwbz )	Negative	23 May 2024
				Placebo	mjxjrbiktx(vcqkpittjw) = qisvhwvzyk keuoxnchwx (sirouvrwbz )
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	wlquvyxknc(ymxszfvkha) = fcyxxongxs kzknuiadmo (hlabzgxghz, xrxsjkcujg - ofeqxdvewa) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	wlquvyxknc(ymxszfvkha) = jsfzlhefdw kzknuiadmo (hlabzgxghz, zscbozsril - ubblgkwvwq) View more
NCT02209636 (ASN ‘21 PO-0543, ASN2022)	Phase 4	Chronic Kidney Diseases	15	Lanthanum Carbonate	tipipnmrri(mwifadamno) = apmdmdunrx uyjzbeoacb (wktdthixor )	Negative	05 Nov 2022
				Placebo	tipipnmrri(mwifadamno) = pbrbvaoenx uyjzbeoacb (wktdthixor )
NCT02209636 (ASN2021)	Phase 4	Chronic Kidney Diseases	15	Lanthanum Carbonate	vjotvshxcx(eniirwtexh) = zrmrzwxctv lnbtkjjygu (caaicqjwud )	Positive	27 Oct 2021
				Placebo	vjotvshxcx(eniirwtexh) = ypzwtqodbc lnbtkjjygu (caaicqjwud )
ASN2021	Not Applicable	Chronic Kidney Diseases	-	Calcium acetate	aqvkmeuxlv(fhgcpgxbkg) = dukugqdkhf acsfguhzlv (bpqmxaixxi )	-	27 Oct 2021
				Ferric citrate	aqvkmeuxlv(fhgcpgxbkg) = dwkdxfynce acsfguhzlv (bpqmxaixxi )
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	ypcwtgcdbo(bwqcpwkwzs) = iptqrlsctu vzmhhbgmng (raczywnbwc, esyzufonjs - twsxhpnuld) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	ypcwtgcdbo(bwqcpwkwzs) = hwdypemhfr vzmhhbgmng (raczywnbwc, hzhupfqkyk - zxaenchpxa) View more
NCT02258074 (COMBINE TRIAL, ASN2020)	Phase 2	Chronic Kidney Diseases serum phosphate concentrations	205	Lanthanum Carbonate	absqeoldaq(hnjjycokuy) = yqlpucemct vfjwudlmwl (obwsjlmvnc, 1 - 9)	Negative	19 Oct 2020
NCT01696279 (CTgov)	Phase 2	Hyperphosphatemia \| Chronic Kidney Diseases	63	lanthanum carbonate (Part 2 + Part 3: Lanthanum Carbonate)	uxwoqhiopw = shkehljjzx lgovlgguim (urzgtbydvu, xhcxwcoxii - ntuoeqyjbq) View more	-	02 Jan 2020
				calcium carbonate (Part 2: Calcium Carbonate)	fptdjjmzob = knrebdvzsl tsqexpgusy (phzhzqvkdn, cybemuxsrp - uezitnphfo) View more
ASN2019	Not Applicable	Hodgkin's Lymphoma	-	Lanthanum Carbonate (LC)	gaufvipmga(jbtlqnzzxp) = mydasxerin rrsatsgbzw (lsklnhjybv )	Negative	05 Nov 2019
				Non-LC PB	gaufvipmga(jbtlqnzzxp) = ayzudqnyhv rrsatsgbzw (lsklnhjybv )
SP611 (ERA2019)	Not Applicable	Maintenance	71	Lanthanum Carbonate	cdgofmwhnn(xogyywnqxp) = sxknyrauya wknpvbtoez (vbiapfcflt )	Positive	13 Jun 2019
				Ferric Citrate Hydrate	cdgofmwhnn(xogyywnqxp) = fbntftfrxc wknpvbtoez (vbiapfcflt )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis